Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20729579 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL200722 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL26893965 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL8304417 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL27043970 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL692637 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL200978 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL72827 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL13216436 | 0.91 | HSD17B10 (0.45) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL2965236 | 0.91 | HSD17B10 (0.45) | CHRM2CHRM1CHRM3EPHX1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4705302-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4606377-A2 | NOVEL AMINO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4219478-B1 | METHOD OF PREPARING AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-11 | — | — | EP | disclosed |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12215116-B2 | Arginase inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-02-04 | — | — | US | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-6770741-B1 | USEFUL IN TREATING CONDITIONS AND DISEASES OF A MAMMAL AND HUMAN IN WHICH AN EXCESS OF BRADYKININ OR RELATED KININS ARE PRODUCED OR INJECTED SUCH AS BY INSECT BITES | SCIOS INC. | 2004-08-03 | — | — | US | disclosed |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | HAMANN LAWRENCE (US) | 2004-05-13 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-6670386-B2 | For therapy of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-20 | — | — | US | disclosed |
| US-6288036-B1 | ANTIINFLAMMATORY, ANTIASTHMATIC, ANTIALLERGEN, AND ANALGESIC AGENTS; ARGININE-CONTAINING NONA- OR DECAPEPTIDES | SCIOS INC. | 2001-09-11 | — | — | US | disclosed |
| EP-0618810-B1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-0618809-B1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CHRM2 533/4885CHRM1 537/4885CHRM3 480/4885 |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CHRM2 611/4885CHRM1 767/4885CHRM3 179/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | CHRM2 4118/4885CHRM1 4045/4885CHRM3 4031/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CHRM2 489/4885CHRM1 461/4885CHRM3 423/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | CHRM2 2762/4885CHRM1 2001/4885CHRM3 2036/4885 |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CHRM2 636/4885CHRM1 611/4885CHRM3 562/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | CHRM2 195/4885CHRM1 115/4885CHRM3 559/4885 |
| US-12215116-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, PRMT1 | CHRM2 726/4885CHRM1 738/4885CHRM3 1948/4885 |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CHRM2 636/4885CHRM1 611/4885CHRM3 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.